• Citer

Gene signature-MELD score and alcohol relapse determine long-term prognosis of patients with severe alcoholic hepatitis

par Deltenre, Pierre ;Trepo, Eric ;Fujiwara, Naoto;Goossens, Nicolas ;Marot, Astrid;Dubois, Margaux;Spahr, Laurent;Henrion, Jean;Moreno, Christophe ;Hoshida, Yujin
Référence Liver international
Publication Publié, 2019-04-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Background: The gene-signature-model for end stage liver disease (gs-MELD) score has been shown to be a strong predictor of 6-month survival in severe alcoholic hepatitis (AH). Currently, only a few studies have evaluated the long-term prognosis of patients with severe AH. Aim: To assess the prognostic value of the gs-MELD score at 5 years in patients with severe AH. Methods: Forty-eight consecutive patients with AH (25 males, median age 52 years [95% IC: 48-56]) were included. Results: The median gs-MELD score was 2.6 (95% CI: 2.2-3.0). According to the gs-MELD score, 22 patients (46%) were considered to have a poor prognosis. During a median follow-up of 29 months (95% CI: 4-43), 19 patients (40%) were abstinent and 24 patients (50%) died. At 5 years, rates of survival were 61% (95% CI: 41-81) and 26% (95% CI: 11-55) in patients with low and high gs-MELD scores (P =.001), and 81% (95% CI: 58-96) and 22% (95% CI: 10-47) in abstainers and in consumers (P <.001) respectively. In multivariable competing risk regression modelling, gs-MELD score (subdistribution hazard ratio: 5.78, 95% CI: 2.17-15.38, P <.001) and recurrent alcohol consumption (subdistribution hazard ratio: 12.18, 95% CI: 3.16-46.95, P <.001) were independently associated with 5-year mortality. Conclusions: Both gs-MELD score and alcohol consumption drive AH long-term prognosis. The gs-MELD score may guide the development of molecularly targeted therapies in AH.